Insider Interviews and
Exhibit Hall Insights

Big Pharma Steadying the CGT Ship Through Turbulent Waters

Click to play video

Ryan Murray’s keynote presentation at BPI West in San Diego, California in March reflected on the fragile nature of the cell and gene therapy (CGT) space. But despite numerous headwinds – approvals down, investment volatility, job lay-offs, adverse events etc – Murray, a senior consultant at ValSource, remained cautiously optimistic for the future of the sector.

To find out more, BioProcess Insider sat bar side with Murray and a couple of cold Red Trolley ales on the show floor, where he waxed lyrical about the current state of the industry and his hopes and forecasts for the future.

Avid Bioservices Transforms the CDMO Experience

Click to play video

Kenny Smart, Senior Director of Business Development for Viral Vector at Avid Bioservices shares the history and capabilites of Avid Bioservices at BioProcess International US West 2025 in San Diego, CA. He highlights the viral vector product capabilities - AAV, lentivirus, adenovirus, and any of the oncolytic viruses - for the purpose of gene therapies or gene-modified cell therapies. With 30 years of experience in the industry, they have an expert team of scientists and engineers working in state-of-the-art facilities, Smart says.

"We are customer focused," says Smart. "Every client that walks in the door with us we create a personalized process for them and their therapeutic. And we make sure they have a path to commercialization in the current phase and in the future."

Saving Sophie: Harnessing natural killer cells to save lives

Click to play video

Among the many technical experts and industry thought leaders presenting at BioProcess International (BPI) West in San Diego, California in March 2025, a morning address by Tracy Ryan – neither scientist nor consultant – shined for its emotional resonance.

Ryan addressed delegates as the mother of a young girl named Sophie who was diagnosed with a brain tumor at 8 months old. Working with Anahid Jewett out of UCLA, Ryan helped spearhead the launch of cell therapy developer NKore Biotherapeutics, which has created an oncology immunotherapy platform based on activating natural killer (NK) cells.

Process Intensification Made Simple: Innovations and Capabilities of M++

Click to play video

Zuwei Jin, VP of Business Development at LISURE explains the advantages of the M++ system at BioProcess International US West 2025 in San Diego, CA.

M++ is a pilot-scale modular benchtop system that can run Chromatography, TFF, Depth Filtration (NFF), SPTFF/SSTFF, inline dilution (ID), and various process intensifications (PI) including 4C Continuous chromatography and many cycle-time-reducing integrated processes. M++features industrial cGMP compliant ASME BPE hygienic flow paths, innovative configurations for inline buffer exchanging and unclarified feed loading for chromatography, and industrial DCS control platforms, all for built-in scalability from benchtop to commercial production. Common data management framework on top of DCS provides much desired support for CMC submission and is aligned with the industrial trend towards digital transformation.

The Impact Elution pH can have on Product Quality of Fc Containing Proteins

Click to play video

Karen Green, Sr Marketing Manager, Ecolab Life Sciences explains the Ecolab poster "The Impact of Elution pH on Product Quality of Fc-Containing Proteins" at BioProcess International US West 2025. The Jetted A50 HipH allows for elution with higher yields and capabilities than traditional Protein A chromatography columns for more complex molecules such as bispecifics and Fc-containing molecules.

Download the full poster here.

Panel Experts Delve into the State of the Industry at BPI West

Click to play video

Roger Lias, commercial head of Biologics at Kymanox, Cassidy Cantin, associate partner at Latham BioPharm Group, and Andrew Harmon, senior consultant at Latham BioPharm Group, joined BioProcess International's own Dan Stanton on stage at BPI West to discuss the latest trends in the bioprocess space.

The panel dived deep into the impact of the new US administration on the biopharma industry, highlighting unpredictability and potential policy changes. Key points included the uncertainty surrounding NIH funding, the potential for increased onshoring due to the BIOSECURE Act, and the broader implications for global supply chains. The discussion also covered the economic and strategic considerations for companies, the potential for increased investment in India and Korea, and the long-term resilience of the industry. The panelists expressed cautious optimism, emphasizing the need for strategic planning and risk mitigation in the face of ongoing policy changes and economic uncertainties.